Role of biologics in oral diseases- A therapeutic intervention

Ruhi Sidhu¹, Ravindra Setru Veerabhadrapa², Navdeep Kooner Shergill³

¹Assistant Professor, ²Professor, ³Associate Professor, ¹³Dept. of Oral Medicine and Radiology, ¹DAV Dental College and Hospital, Tatul, Oachghat, Solan, Tatul, Himachal Pradesh, ²Teerthanker Mahaveer Dental College, T.M.U, Moradabad, Uttar Pradesh, ³Rayat and Bahra Dental College and Hospital, Mohali, Punjab, India

*Corresponding Author: Ruhi Sidhu
Email: ruhi.sidhu@yahoo.com

Abstract
Biologic therapies are innovative treatments involving immune modulating agents. There are classified into three broad categories: tumour necrosis factor-alpha inhibitors, lymphocyte modulators and interleukin inhibitors. These are increasingly being used in the treatment of inflammatory immune mediated conditions and neoplastic conditions. However, their role in oral diseases is limited as they are mainly used in refractory cases. Important side effects of Biologic agents are severe life threatening infections and their high economic cost. Therefore, patients receiving biologic therapies should be carefully guided and monitored to avoid potential complications. Hence, a proper understanding of these agents is required. The purpose of this review is to give a brief outlook on the biologic agents and their use in oral diseases.

Keyword: Oral diseases, Biologic agents, Refractory patients.

Introduction
Biologic Agents (BAs) are a group of drugs that are generated by recombinant biotechnology. They are also known as Targeted Immune Modulators and Biological Response Modifiers. They consist of humanised or chimaeric monoclonal antibodies or variant fusion proteins that block specific pathways involved in the pathophysiology of immune mediated and neoplastic diseases. They are used in the treatment of a variety of inflammatory immune-mediated conditions i.e they have an anti-inflammatory or immunosuppressive action. The basis of treatment with BAs is pathogenesis-based and not just organ- based palliative therapy.¹²

The three broad classes¹² of BAs are:
1. Proinflammatory cytokine: Tumour Necrosis Factor-Alpha (TNF-α) inhibitors e.g. infliximab, etanercept, and adalimumab.
2. An Antibody: Interleukin (IL) inhibitors which inhibits IL-12/IL-23 e.g. ustekinumab,
3. Fusion Proteins: Lymphocyte Modulators
   a. T-cell modulators, e.g. alefacept and efalizumab.
   b. B-cell modulators, e.g. rituximab.

A variety of BAs are used for oral diseases that include Adalimumab, Etanercept, Infliximab, Alefacept, Efalizumab, Rituximab, Epratuzumab and Basiliximab. Mode of administration and schedules vary but overall they are all available in injectable preparations.
1. Infliximab and Rituximab: Periodic intravenous infusions (IV).
2. Etanercept and Adalimumab: Regular subcutaneous (SC) injections (biweekly, weekly, every 2 weeks or monthly)
3. Alefacept: Weekly intramuscular (IM) injections.²

Use of Biologic Agents in Oral Diseases
Oral Lichen Planus (OLP)
It is a chronic inflammatory disease that involves skin and mucosa. Although exact etiology is unknown, but the role of immunologic system, in the pathogenesis is well documented. Different drugs have been used for treatment of OLP broadly in two forms, topical or and systemic which include corticosteroids, immunosuppressives, retinoids, and immunomodulators etc. Biologic agents have been recently introduced as a treatment modality in a limited number of cases of severe recalcitrant OLP unresponsive to other treatments.⁵⁸ According to various studies conducted the following drugs (Table 1) have been used. In a case study titled "Lichen planus secondary complications associated with the use of biologic therapy for rheumatoid arthritis” by Chiriac A et al ¹¹ in 2013, a known patient of rheumatoid arthritis and lichen planus was studied for the possibility that lichen planus lesions could potentially become complicated by secondary infections in patients treated with Etanercept. However, it was concluded that the case was not a lichen planus induced by Etanercept, but it was aggravated and secondarily infected with Methicillin-sensitive Staphylococcus during the therapy. The use of BAs as a treatment modality for OLP, is still limited. Hence, less expensive drugs more familiar to everyday use are preferred.

Oral Pemphigus Vulgaris
Oral Pemphigus vulgaris (OPV) is an acquired autoimmune disease in which circulating IgG antibodies target desmosomal proteins desmoglein 1 and 3 to produce acantholysis, intraepithelial, & mucocutaneous blistering. Oral mucosa is the first and most common site affected. First line of treatment is systemic steroids.²⁰²² In cases of severe OPV, after a number of one arm clinical trials, a promising new agent with promising results is Rituximab, but all authors underline the risk of serious infections.²³²⁹

International Dental Journal of Student’s Research. April-June 2019;7(2):29-34
The mode of action of Rituximab is however unclear but it is proposed that is works by eliminating the B-cell precursors which results in reduction of plasma cells secreting auto-antibodies against the main targets desmoglein 1 and 3; and it decrease desmoglein-specific T-cells. 36,53 On reviewing literature, the use of infliximab and etanercept in oral and cutaneous pemphigus has also demonstrated beneficial result. 34-36

**Mucous Membrane Pemphigoid**

Mucous membrane pemphigoid (MMP) is an autoimmune subepithelial vesiculobullous condition in which auto-antibodies target base-membrane auto-antigens (against proteins of the hemidesmosomes). It is characterized clinically by the development of blisters and erosions. The first line of treatment is with steroids and immunosuppressants. On reviewing literature, various case series-studies conducted in 2010, 2011 demonstrated the role of an anti-B cell agent, Rituximab in remission of MMP. Its mode of action is by reducing the population of autoantibody by producing B-cells. The use of anti-TNF agents infliximab and etanercept has also been reported. 37-41 Use of anti-TNF agents can be based on the rationale that in MMP there is formation of subepithelial blistering which is caused by multiple cytokines including TNF. Hence, BAs can be considered a “third-line” treatment modality in severe cases of MMP. 42 To use BAs as a conclusive treatment modality further research is required.

**Recurrent aphthous Stomatitis**

Recurrent aphthous stomatitis, or RAS, is a common and indolent inflammatory ulcerative condition in which recurring ovoid or round painful oral mucosal ulcers cause pain on eating, swallowing and speaking. 43 There are numerous factors contributing to etiology of RAS based on which various treatment protocols are followed. Amongst these are anti-inflammatory drugs, steroids, antivirals, antibacterials or vitamin supplements. In persistent recurrent aphthous stomatitis, several studies have concluded the positive effect of the use of BAs namely, infliximab and etanercept but are very expensive therapeutic option. 44-49 These are drugs are effective because TNF is the major cytokine involved in the pathogenesis of aphthae. 50-51

**Behçet’s Disease**

Behçet’s disease is a rare autoinflammatory vasculitis with a triad of clinical characteristics of oral aphthous-like ulcers, genital ulcers, ocular uveitis. As a systemic disease, it can also involve gastrointestinal tract, major blood vessels, musculoskeletal system and central nervous system. Hence, various subtypes are referred to as: Ocular uveitis, Neuro-Behçet, Entero-Behçet, Major Vessel Disease, & Joint Involvement. The drug of choice includes steroids and traditional immunosuppressive drugs. However, these drugs are not effective in refractory cases like some patients with ocular, intestinal, vascular and neurologic involvement. Therefore, BAs can be regarded as a reasonable alternative solution (Table 2). Anti-TNF-α inhibitors have proven to be beneficial in ophthalmic, neurologic and joint involvement cases.52-55 The most frequently prescribed Anti-TNF agent is interferon alpha 2a and occasionally used include infliximab, rituximab, tocilizumab, canakinumab, rituximab and anakinra

| Category | Name of Drug | Dose | Mode of Action | Drawbacks |
|----------|--------------|------|---------------|-----------|
| **Anti T-Cell Agents**<sup>9-13</sup> | Alefacept | 15 mg/week 1IM for 12 weeks | Interacts with LFA-3 and T-cell activation. | Withdrewn since 2009 due to the progressive multifocal leukoencephalopathy (PML) risk, hence no other data exist. |
| | Efalizumab | 0.7 mg/kg/week for 3-10 weeks | Interacts with the leukocyte-function antigen-1 (LFA-1) and T-cell activation. | |
| **Anti-TNF Agents**<sup>14-17</sup> | Etanercept | 25 mg/twice weekly | TNF has been proposed to be one of the major cytokines involved in the pathogenesis of OLP | Lichenoid reactions occurrence because of the deregulation in the balance between TNF and interferon-alpha (INF-α). |
| | Adalimumab | 40mg every other week | | |
| **Anti IL-2 Receptor Agent**<sup>18</sup> | Basiliximab | Bolus intravenous infusion of 20 mg, 2 doses, 4 days apart | Interferes with Tcell regulation | The cost and infection risk of basiliximab probably would form a barrier to planning appropriate clinical studies. |
Psoriasis

Psoriasis is an immune mediated chronic inflammatory skin condition clinically characterized by silver white scaly appearance of the skin with erythematous base. TNF-a blockade is an established treatment strategy as the main pathogenesis of psoriasis involves activation of TNF alpha and IFN alpha. Hence, the anti-TNF BAs include infliximab, etanercept, adalimumab and golimumab. However, patients receiving treatment with these agents should be monitored as well as educated about serious infections.

Sjögren’s Syndrome

Sjogren syndrome (SS) is a common immune-related inflammatory disease that most commonly involves the tear and saliva glands (primary or secondary when it coexists with other rheumatoid or other autoimmune diseases). Clinically it is characterised by xerostomia (because of hyposalivation) and dryness of eyes. Some patients experience dryness in the nasal passages, throat, vagina and skin. Patients are advised symptomatic treatment which includes: Lubrication of dry eyes with artificial tear drops & stimulation of salivary flow by sugar free lozenges. Lubricant gels are used to treat vaginal dryness and dry skin with moisturizing lotions. Systemic corticosteroids and immunosuppressive drugs such as cyclophosphamide are used for severe extraglandular diseases. BAs effective in SS are rituximab and epratuzumab. Their mode of action is based on the fact that in the pathogenesis of SS, B-cells infiltrate salivary gland and clonal populations of these cells possibly cause salivary gland lymphomas that develop in SS, therefore, anti B-cell agents. Targeting B-lymphocytes appears as a treatment for severe cases of primary SS.

Rheumatoid Arthritis

Rheumatoid arthritis (RA) is an autoimmune inflammatory condition affecting small joints of hand (knuckles), wrists, feet etc. Treatment of RA has undergone tremendous change in the last few years. No single treatment is there for the patients. Rather a combination of treatments or a change in treatment is required. The conventional treatment begins with disease modifying antirheumatic drugs (DMARDs) followed by Methotrexate (MTX), administered alone or with DMARDs. BAs mainly anti-TNF agents, infliximab, etanercept, adalimumab and golimumab, when administered with MTX, show enhanced efficacy. Lymphocyte modulators like rituximab, which targets CD20+ B cells, may also be effective when combined with MTX. On reviewing literature, it was noted that biologic monotherapy has limited approval as a treatment modality for RA.

Biologic Agents in a dental setting

Nowadays a number of patients on biologic agents visit dental setups i.e oral medicine, oral pathology, oral and maxillofacial surgery etc. Biologic therapy is contraindicated in patients who are hypersensitive to the agent, have active infections, have heart associated conditions, are pregnant, have a history of bleeding tendency or have active infections. Biologics are not recommended in patients with infections which may be locally invasive or may spread systemically (i.e., endocarditis, active uveitis, cervicofacial cellulitis). Biologics are also contraindicated in patients with a history of infections that are difficult to eradicate, or patients who have active infections that may be associated with a high risk of microbial translocation (ex. HIV, fever). Biologics are best avoided when patients present with active infections, multiple infections, or infections related to oral disease.

Table 2: Various Biologic Agents used for the treatment of Behcet’s Disease

| Types of Behcet’s disease | Biologic agents used | Added benefits | Adverse effects |
|---------------------------|----------------------|----------------|----------------|
| Ocular disease            |                      |                |                |
| Posterior uveitis         | Interferon alpha (IFN alpha) & Anti-TNF Agents | Revascularization of retinal veins Regression of neovascularization | Cytopenia Depression |
| Retinal vasculitis        | Interferon alpha (IFN alpha) & Anti-TNF Agents |                    |                |
| Active uveitis            | Interferon alpha (IFN alpha) |                    |                |
| Refractory uveitis        | Anti-TNF Agents: Etanercept, Adalimumab & Infliximab | Reduction in ocular attacks Decrease in mean background retinal/disc vascular leakage |                |
| Neuro-behct                | Severe cases         |                |                |
| Retinal vasculitis        | Interferon alpha (IFN alpha) & Anti-TNF Agents | Revascularization of retinal veins Regression of neovascularization | Cytopenia Depression |
| Active uveitis            | Interferon alpha (IFN alpha) |                    |                |
| Refractory uveitis        | Anti-TNF Agents: Etanercept, Adalimumab & Infliximab | Reduction in ocular attacks Decrease in mean background retinal/disc vascular leakage |                |
| Major Vessel Disease      | Refractory cases     |                |                |
| Aortic involvement,       | Anti IL-6 Receptor Agent: Tocilizumab | Maintains remission |                |
| Arterial thrombosis &     | Infliximab           | Maintains remission |                |
| Retinal Vasculitis        | Or Infliximab+ Methotrexate |                |                |
| Bilateral Pulmonary       | Adalimumab           |                |                |
| Arterial Aneurysm         |                      |                |                |
| Joint involvement         | Arthritis            |                |                |
| Ankylosingpondylitis with | Infliximab           | Maintains remission |                |
| Behcet's disease          | Anti-TNF agents      |                |                |
problems, pregnancy and lactation or malignancy. Hence, whenever a patient visits a clinic, a detailed case history should be taken to avoid any serious complications due to intervention dental treatment. Before initiating biologic therapy, it is advised to undergo a formal dental evaluation and treatment to exclude any focus of chronic infection. On encountering a patient receiving biologic therapy, patient should be educated and guided about the possible adverse effects, potential opportunistic infections etc. Patients on biologic therapy, undergoing endodontic treatment, periodontal surgery or other invasive procedures should be examined, evaluated and treated with utmost care to avoid any serious complications.  

Conclusion

In recent years, immune mediated oral diseases, which have become resistant to conventional therapy or in severe forms are not treated with usual drugs, the line of treatment is shifting towards biologic therapy. The rationale to opt for BAs in various diseases is justified by the pathogenesis of the disease. Biologic agents have considerable side effects, especially infections, hence, studies should be conducted to establish their efficacy and safety. Lastly, the cost of these agents is very high and should be considered prior to their clinical use. To summarize BAs in oral diseases could assist in clinical decision making, revolutionizing the treatment protocols and improving the quality of life of a patient.

Conflict of Interest: None.

References

1. Eleni A, Georgakopoulou, Dimitrios Andreadis, Efthymios Arvanitidis, Panagiota Loumou. Biologic Agents and Oral Diseases – An Update on Clinical Applications. Acta Dermato-Venereol 2013;21(1):24-34.
2. O’Neill ID, Scully C. Biologics in oral medicine: principles of use and practical considerations. Oral Dis 2012;18:525-36.
3. Chong BF, Wong HK. Immunobiologics in the treatment of psoriasis. Clin Immunol 2007; 123: 129–136.
4. Jackson JM, TNF-alpha inhibitors. Dermatol Ther 2007;20:251-64.
5. González-Moles MA, Scully C, Gil-Montoya JA. Oral lichen planus: controversies surrounding malignant transformation. Oral Dis 2008;14:229-43.
6. Lodi G, Scully C, Carrozzo M, Griffiths M, Sugarman PB, Thongprasom K et al. Current controversies in oral lichen planus: report of an international consensus meeting. Part 1. Viral infections and etiopathogenesis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;100:40-51.
7. Scully C, Carrozzo M. Oral mucosal disease: lichen planus. Br J Oral Maxillofac Surg 2008;46:15-21.
8. Thongprasom K, Carrozzo M, Furness S, Lodi G. Interventions for treating oral lichen planus. Cochrane Database Syst Rev 2011;7:CD001168.
9. Cheng A, Mann C. Oral erosive lichen planus treated with efalizumab. Arch Dermatol 2006;142:680-2.
10. Fivenson DP, Mathes B. Treatment of generalized lichen planus with alefacept. Arch Dermatol 2006;142:151-2.
11. Griffiths CE. T-cell-targeted biologicals for psoriasis. Curr Drug Targets Inflamm Allergy 2004;3:157-61.
12. Bohm M, Luger TA. Lichen planus responding to efalizumab. J Am Acad Dermatol 2007;56(5):S92-93.
13. Farhi D, Dupin N. Pathophysiology, etiologic factors, and clinical management of oral lichen planus Part I. Facts and controversies. Clin Dermatol 2010;28:100-8.
14. Yarom N. Etanercept for the management of oral lichen planus. Am J Clin Dermatol 2007;8:121.
15. Chao TJ. Adalimumab in the management of cutaneous and oral lichen planus. Cutsis 2009;84:325-8.
16. Zhou G, Xia K, Du GF, Chen XM, Xu XY, Lu R, et al. Activation of nuclear factor-kappa B correlates with tumor necrosis factor-alpha in oral lichen planus: a clinicopathologic study in atrophic-erosive and reticular form. J Oral Pathol Med 2009;38:559-64.
17. Asarch A, Gottlieb AB, Lee J, Masterpol KS, Scheiman PL, Stadecker MJ, et al. Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists. J Am Acad Dermatol 2009;61:104-11.
18. Rebora A, Parodi A, Muralio G. Basiliximab is effective for erosive lichen planus. Arch Dermatol 2002;138:1100-1.
19. Chiriac A, Foia L, Anca E, Chiriac, Ancuța C, Manea P, Profiøre L et al. Lichen planus secondary complications associated with the use of biologic therapy for rheumatoid arthritis. Rom J Morphol Embryol 2013;54(3):829–31.
20. Gniadecki R. Desmoglein autoimmunity in the pathogenesis of pemphigus. Autoimmunity 2006;39:541-7.
21. Camacho-Alonso F, Lopez-Jornet P, Bermejo-Fenoll A. Pemphigus vulgaris. A presentation of 14 cases and review of the literature. Med Oral Patol Oral Cir Bucal 2005;10:282-8.
22. Martin LK, Werth V, Villanueva E, Segall J, Murrell DF. Interventions for pemphigus vulgaris and Rev 2009.
23. Carson PJ, Hameed A, Ahmed AR. Influence of treatment on the clinical course of pemphigus vulgaris. J Am Acad Dermatol 1996;34:645-52.
24. Bhat R, Sharma VK, Ramam M, Kumar A. Cyclophosphamide pulses with oral prednisolone in the treatment of pemphigus: a pilot study. Dermatol Online J 2005;11:4.
25. Ahmed AR, Spigelman Z, Cavarciina LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006;355:1772-9.
26. El Tal AK, Posner MR, Spigelman Z, Ahmed AR. Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris. J Am Acad Dermatol 2006;55:449-59.
27. Heizmann M, Itin P, Werdel M, Borradori L, Bargezzi MJ. Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. Am J Hematol 2001;66:142-4.
28. Borradori L, Lombardi T, Samson J, Girardet C, Saurat JH, Hugli A. Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma-associated paraneoplastic pemphigus. Arch Dermatol 2003;139:269-72.
29. Cianchini G, Corona R, Frezzolini A, Ruffelli M, Didona B, Puddu P et al. Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature. Arch Dermatol 2007;143:1033-8.
30. Mouquet H, Musette P, Gougeon ML, Jacquot S, Lemerter B, Anca E. Chiriac, et al. Lichen planus secondary complications associated paraneoplastic pemphigus. Rom J Morphol Embryol 2009;58:501.
31. Mignon M, Fortuna G, Leuci S. Oral pemphigus. Minerva Stomatol 2009;58:501-8.
32. Zambruno G, Borradori L. Rituximab immunotherapy in pemphigus: therapeutic effects beyond Becl depletion. J Invest Dermatol 2008;128:2745-7.
33. Diaz LA. Rituximab and pemphigus - a therapeutic advance. N Engl J Med 2007;357:605-7.
Role of biologics in oral diseases- A therapeutic intervention

34. Shetty A, Marcum CB, Glass LF, Carter JD. Successful treatment of pemphigus vulgaris with etanercept in four patients. J Drugs Dermatol 2009;8:940-3.

35. Jacobi A, Shuler G, Hertl M. Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab. Br J Dermatol 2005;153:448-9.

36. Pardo J, Mercader P, Mahiques L, Sanchez-Carazo JL, Oliver V, Fortea JM et al. Infliximab in the management of severe pemphigus vulgaris. Br J Dermatol 2005;153:222-3.

37. Scully C, Lo Muzio L. Oral mucosal diseases: mucous membrane pemphigoid. Br J Oral Maxillofac Surg 2008;46:358-66.

38. Lourari S, Herve C, Doffoel-Hantz V, Meyer N, Bulai-Livideau C, Viraben R, et al. Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients. J Eur Acad Dermatol Venereol 2010;25:1238-40.

39. Le Roux-Villet C, Prost-Squarcioni C, Alexandre M, Caux F, Pascal F, Donn S, et al. Rituximab for patients with refractory mucous membrane pemphigoid. Arch Dermatol 2011;147:843-9.

40. Elmets C. Clinical trial evaluating rituximab in ocular cicatricial pemphigoid NIH. http://clinicaltrials.gov/ct2/home 2008.

41. Laskaris G, Angelopoulos A. Cicatricial pemphigoid: direct and indirect immunofluorescent studies. Oral Surg Oral Med Oral Pathol 1981;51:48-54.

42. Bagan J, Lo Muzio L, Scully C. Mucosal disease series. Number III. Mucous membrane pemphigoid. Oral Dis 2005;11:197-218.

43. Silverman S Jr. Mucosal lesions in older adults. J Am Dent Assoc 2007;138:415-465.

44. Scheinberg MA. Treatment of recurrent oral aphthous ulcers with etanercept. Clin Exp Rheumatol 2002;20:733-4.

45. Robinson ND, Guitart J. Recalcitrant, recurrent aphthous stomatitis treated with etanercept. Arch Dermatol 2003;139:1259-62.

46. Atzeni F, Sarzi-Puttini P, Capsoni F, Mechcia M, Marrazza MG, Carrabba M et al. Successful treatment of resistant Behçet’s disease with etanercept. Clin Exp Rheumatol 2005;23:729.

47. Connolly M, Armstrong JS, Buckley DA. Infliximab treatment for severe orogenital ulceration in Behçet’s disease. Br J Dermatol 2005;153:1073-5.

48. Melikoglu M, Fresko I, Mat C, Özyazgan Y, Gogus F, Yurdakul S, et al. Short-term trial of etanercept in Behçet’s disease: a double blind, placebo controlled study. J Rheumatol 2005;32:98-105.

49. Almazino G, Ben-Chetrit E. Infliximab for the treatment of resistant oral ulcers in Behçet’s disease: a case report and review of the literature. Clin Exp Rheumatol 2007;25(4):S99-102.

50. Natah SS, Hayrinen-Immonen R, Hietanen J, Malmstrom M, Konttinen YT. Immunolocalization of tumor necrosis factor-alpha expressing cells in recurrent aphthous ulcer lesions (RAU). J Oral Pathol Med 2000;29:19-25.

51. Dalghous AM, Freysdottir J, Fortune F. Expression of cytokines, chemokines, and chemokine receptors in oral ulcers of patients with Behçet’s disease (BD) and recurrent aphthous stomatitis is Th1-associated, although Th2-association is also observed in patients with BD. Scand J Rheumatol 2006;35:472-5.

52. Ribi C, Sztajzel R, Delavelle J, Chizzolini C. Efficacy of TNF-alpha blockade in cyclophosphamide resistant neuo-Behçet disease. J Neurol Neurosurg Psychiatry 2005;76:1733-5.

53. Murray PJ, Sivaraj RR. Anti-TNF-alpha therapy for uveitis: Behçet and beyond. Eye 2005;19:831-3.

54. Sfikakis PP, Markomichelakis N, Alpsoy E, Assaad- Khalil S, Bodaghi B, Gul A, et al. Anti-TNF therapy in the management of Behçet’s disease - review and basis for recommendations. Rheumatol Int 2007;27:359-61.

55. Yesil NK, Şahin H, İşık H, Örnec Z, Yazgan S, Tok A et al. Yunus Emre Yandi, Metin Işık, İsmail Doğan. Open J Rheumatol Autoimmune Dis 2015;5:97-103.

56. Kotter, I., Zierhut, M., Eckstein, A., Vontein, R., Ness, T., Gunaydin, İ., et al. Human Recombinant Interferon α-2a for the Treatment of Behçet’s Disease with Sight Threatening Posterior or Panuveitis. Br J Ophthalmol 2003;87:423-31.

57. Kotter, I., Gunaydin, İ., Zierhut, M. and Stubiger, N. The Use of Interferon Alpha in Behçet Disease: Review of the Literature. Semin Arthritis Rheumatism 2004;33:320-335.

58. Keino, H., Okada, A.A., Watanabe, T. and Taki, W. Long Term Efficacy of Infliximab on Background Vascular Leakage in Patients with Behçet’s Disease. Eye 2014;28:1100-6.

59. Kaburaki, T., Namba, K., Sonoda, K.H., Kezuka, T., Keino, H., Fukuhara, T. et al. Ocular Behçet Disease Research Group of Japan Behçet’s Disease Ocular Attack Score 24: Evaluation of Ocular Disease Activity before and after Initiation of Infliximab. Japanese J Ophthalmol 2014:58:120-30.

60. Kanemaru, H., Makino, T., Jinnin, M., Yonemitsu, A., Makino, K. and Ihn, H et al. Case of Neuro-Behçet’s Disease Successfully Maintained a Remission Using Infliximab for 2 Years. J Rheumatol 2013;40:632-634.

61. Hirohata, S. and Kikuchi, H. Changes in Biomarkers Focused on Differences in Disease Course or Treatment in Patients with Neuro-Behçet’s Disease. Int Med 2012;51:3359-65.

62. Shapiro, L.S., Farrell, J. and Haghighi, A.B. Tocilizumab Treatment for Neuro-Behçet’s Disease, the First Report. Clin Neurol Neurosurg 2012;114:297-8.

63. Hatemi, G., Silman, A., Bang, D., Bodaghi, B., Chamberlain, A.M., Gul, A et al., EULAR Expert Committee EULAR Recommendations for the Management of Behçet Disease. Ann Rheumatic Dis 2008;67:1656-62.

64. De Cassan, C., De Vroye, B., Dussault, C., Hachulla, E., Buche, S. and Colombel, J.F. Successful Treatment with Adalimumab in a Familial Case of Gastrointestinal Behçet’s Disease. J Crohn’s Colitis 2011;5:364-8.

65. Arityaichapanich, A., Berkelhammer, C. and Nicola, H. Intestinal Behçet’s Disease: Maintenance of Remission with Adalimumab Monotherapy. Inflamm Bowel Dis 2009;15:1769-71.

66. van Laar, J.A., Missotten, T., van Dalee, P.L., Jamnikski, A., Baarsma, G.S. and van Hagen, P.M. Adalimumab: A New Modality for Behçet’s Disease? Ann Rheumatic Dis 2007;66:565-6.

67. Shimizu, Y., Takeda, T., Matsumoto, R., Yoshida, K., Nakajima, J., Aoyama, J et al. Clinical Efficacy of Adalimumab for a Postoperative Marginal Ulcer in Gastrointestinal Behçet Disease. Nihon Shokakibyo Gakki Zasshi 2012;109:774-80.

68. Sylwestrzak, G., Liu, J., Stephenson, J.J., Ruggieri, A.P. and De Vries, A. et al. Considering Patient Preferences When Selecting Anti-Tumor Necrosis Factor Therapeutic Options. Am Health Drug Benefits 2012;6:9-81.

69. Tanida, S., Inoue, N., Kobayashi, K., Naganuma, M., Hirai, F., Izuika, B et al. Adalimumab for the Treatment of Japanese Patients with Intestinal Behçet’s Disease. Clin Gastroenterol Hepatol 2015;13:940-983.

70. Schäfer, V.S. and Zweizena, J. Biologic Treatment of Large-Vessel Vasculitides. Curr Opin Rheumatol 2012;24:31-7.

71. Adler, S., Baumgartner, I. and Villiger, P.M. Behçet’s Disease: Successful Treatment with Infliximab in 7 Patients with Severe Vascular Manifestations. A Retrospective Analysis. Arthritis Care Res 2012;64:607-11.
72. Lee, S.W., Lee, S.Y., Kim, K.N., Jung, J.K. and Chung, W.T. Adalimumab Treatment for Life Threatening Pulmonary Artery Aneurysm in Behçet Disease: A Case Report. *Clin Rheumatol* 2010;29:91-3.

73. Donghi, D. and Mainetti, C. Infliximab for the Treatment of Refractory Adamantiades-Behçet Disease with Articular, Intestinal, Cerebral and Ocular Involvement. *Dermatol* 2010;220:282-6.

74. Smith CH, Anstey AV, Barker JN. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. *Br J Dermatol* 2009;161:987–1019.

75. Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjogren syndrome. *Arch Intern Med* 2004;164:1275-84.

76. Pollard RP, Pijpe J, Bootsma H, Spijkervet FK, Kluijn PM, Roodenburg JL, et al. Treatment of mucosa-associated lymphoid tissue lymphoma in Sjogren’s syndrome: a retrospective clinical study. *J Rheumatol* 2011;38:2198-208.

77. O’Neill I, Scully C. Biologics in oral medicine: Sjogren syndrome. *Oral Dis* 2012. epub ahead of print

78. Paul Emery, Anthony Sebba, Tom W J Huizinga. Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis. *Ann Rheum Dis* 2013;0:1–8. doi:10.1136/annrheumdis-2013-203485

79. Biologics The story so far: A Patient Guide to Biologic Therapies in the Treatment of Rheumatoid Arthritis www.nras.org.uk SEP2013 – 334.

**How to cite this article:** Sidhu R, Veerabhadrappa RS, Shergill NK. Role of biologics in oral diseases- A therapeutic intervention. *Int Dent J Student’s Res* 2019;7(2):29-34.